RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy
K. Song, K. Edgar, E. Hanan, M. Hafner, J. Oeh, M. Merchant, D. Sampath, M. Nannini, R. Hong, L. Phu, W. Forrest, E. Stawiski, S. schmidt, N. Endres, J. Guan, , L. Friedman
The paper shows that GDC-0077 and taselisib degrade mutant PI3K alpha via HER2-dependent mechanisms, enhancing efficacy in PIK3CA-mutant breast cancer.
bioRxiv · May 12, 2021Cancer Biology